Skip to main content
丹娜生物 logo

丹娜生物 — Investor Relations & Filings

Ticker · 920009 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 61 across all filing types
Latest filing 2026-03-08 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920009

About 丹娜生物

https://www.dynamiker.com/

Dynamiker Biotechnology specializes in the research, development, and manufacturing of in vitro diagnostic (IVD) solutions, focusing on the early detection and monitoring of invasive fungal diseases (IFD). The company offers a comprehensive diagnostic portfolio targeting pathogens such as Aspergillus, Candida, Cryptococcus, and Pneumocystis jirovecii. Its core product lines include (1-3)-β-D-glucan (G test), Galactomannan (GM test), and Cryptococcal Antigen (CrAg) assays, utilizing methodologies like ELISA, lateral flow, and molecular diagnostics. These products are designed to provide rapid, sensitive, and specific results for clinical decision-making. Dynamiker maintains international quality standards and certifications, supporting its commitment to improving diagnostic accuracy and patient management in global healthcare settings.

Recent filings

Filing Released Lang Actions
关于投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details a specific investor relations event held on March 5, 2026, including participants, questions asked, and company responses about business operations, financial performance, product development, and future projects. The content is a Q&A format from an investor relations meeting or strategy session, not a formal financial report or earnings release. It does not contain comprehensive financial statements or formal report data. The document length is 2067 characters, relatively short and focused on investor relations activities rather than a full report. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, rather than an official report or announcement.
2026-03-08 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 丹娜（天津）生物科技股份有限公司 regarding the progress of using idle proprietary funds to purchase wealth management products. It includes extensive tables listing the types, amounts, expected yields, and terms of various financial products purchased, as well as risk control measures and internal authorization details. The document is not a financial report like an annual or interim report, nor is it a transcript, audit, or management report. It is a regulatory disclosure about the company's capital usage and investment activities, specifically about purchasing financial products with idle funds. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (over 14,000 characters) and contains detailed substantive information, not just a brief announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2026-03-03 Chinese
2025年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 年年度业绩快报公告" which translates to "2025 Annual Performance Express Announcement" or "Annual Earnings Quick Report Announcement." It contains preliminary financial data for the year 2025, including revenue, profit, net assets, and earnings per share, but explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the company's full 2025 Annual Report. The document is relatively short (1729 characters) and serves as an initial earnings summary rather than a full comprehensive annual report. It also includes a risk warning about the preliminary nature of the data. This type of document corresponds to an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only, not the full detailed report. FY 2025
2026-02-26 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of idle raised funds for cash management, detailing the investment in bank financial products, risk control measures, and compliance with disclosure rules. It includes specific transaction amounts, counterparties, and investment terms. The document is relatively short (4271 characters) and focuses on disclosing a financing-related update rather than presenting comprehensive financial statements or results. It does not contain full financial reports, audit opinions, or management discussions. Therefore, it fits best as a Capital/Financing Update (CAP) filing type, which covers updates on company fundraising, financing activities, or capital structure changes.
2026-02-05 Chinese
关于使用闲置自有资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 丹娜（天津）生物科技股份有限公司 regarding the progress of using idle proprietary funds to purchase wealth management products. It includes specifics about the authorization, amounts, counterparties, risk controls, and detailed tables of purchased and matured financial products. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory disclosure about capital usage and investment activities, specifically about the company's use of its own funds to buy financial products. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital usage. The document length is substantial and contains detailed financial data about these investments, not just an announcement of a report publication or a certification. Therefore, the classification is CAP with high confidence.
2026-02-03 Chinese
高级管理人员变动公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in senior management personnel of the company 丹娜（天津）生物科技股份有限公司. It details the appointment of a new board secretary and the resignation of the previous one, including compliance and impact statements. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content focuses solely on management changes, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2026-01-21 Chinese

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.